Hiroyuki Suto
Research Subjects
Hiroyuki Suto has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hidetaka Matsuda
Department of Gastroenterology, Fukui General Hospital, 28-16-1, Egami-Cho, Fukui 910-8561, Japan
2 shared publications - Katsushi Hiramatsu
Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
2 shared publications - Kazuto Takahashi
Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan
2 shared publications - Kazuya Ofuji
Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
2 shared publications - Masahiro Ohtani
Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan
2 shared publications - Takuto Nosaka
Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 19 (5) , 1161-1168
Mesenteroaxial gastric volvulus associated with a wandering spleen in an older woman treated with anterior gastropexy and splenectomy: a case report
An 80-year-old woman with Parkinson disease presented with sudden abdominal pain, back pain, and vomiting during a meal. Computed tomography revealed marked gastric dilatation with cranial displacement and rotation of the antrum, consistent with mesenteroaxial gastric volvulus. This was accompanied by an ectopic spleen adjacent to the greater curvature and suspected pedicle torsion, consistent with a wandering spleen. Nasogastric tube passage was initially unsuccessful. Emergency upper gastrointestinal endoscopy achieved gastric decompression and transient detorsion; however, immediate retorsion was observed, and continuous decompression was maintained after successful tube placement. Definitive surgery was performed on hospital day 2. The stomach was reduced and fixed to the abdominal wall via anterior gastropexy; splenectomy was performed due to marked splenic mobility and concerns about recurrent torsion. Histopathological examination revealed congestion and partial hemorrhagic infarction compatible with splenic torsion. The postoperative course was uneventful; the patient was discharged on postoperative day 14 without recurrence during the follow-up. This case underscores that immediate retorsion after endoscopic reduction might warrant prompt definitive surgery with gastropexy and management of a wandering spleen should be individualized according to mobility and splenic viability.
- 7 August 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 19 (5) , 1161-1168
Open AccessMesenteroaxial gastric volvulus associated with a wandering spleen in an older woman treated with anterior gastropexy and splenectomy: a case report
An 80-year-old woman with Parkinson disease presented with sudden abdominal pain, back pain, and vomiting during a meal. Computed tomography revealed marked gastric dilatation with cranial displacement and rotation of the antrum, consistent with mesenteroaxial gastric volvulus. This was accompanied by an ectopic spleen adjacent to the greater curvature and suspected pedicle torsion, consistent with a wandering spleen. Nasogastric tube passage was initially unsuccessful. Emergency upper gastrointestinal endoscopy achieved gastric decompression and transient detorsion; however, immediate retorsion was observed, and continuous decompression was maintained after successful tube placement. Definitive surgery was performed on hospital day 2. The stomach was reduced and fixed to the abdominal wall via anterior gastropexy; splenectomy was performed due to marked splenic mobility and concerns about recurrent torsion. Histopathological examination revealed congestion and partial hemorrhagic infarction compatible with splenic torsion. The postoperative course was uneventful; the patient was discharged on postoperative day 14 without recurrence during the follow-up. This case underscores that immediate retorsion after endoscopic reduction might warrant prompt definitive surgery with gastropexy and management of a wandering spleen should be individualized according to mobility and splenic viability.
- Open Access
- 6 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 863
Pituitary metastasis of hepatocellular carcinoma presenting with panhypopituitarism: a case report
Metastasis to the pituitary gland is extremely rare and is often detected incidentally by symptoms associated with endocrine dysfunction. Breast and lung cancer are the most common primary metastasizing to pituitary gland. Metastasis from hepatocellular carcinoma to the pituitary gland is extremely rare, with only 10 cases having been previously reported. We present here the first case of pituitary metastasis of hepatocellular carcinoma presenting with panhypopituitarism diagnosed by magnetic resonance imaging. We report the case of an 80-year-old Japanese woman who presented with the sudden onset of hypotension and bradycardia after having previously been diagnosed with hepatocellular carcinoma. Based on low levels of pituitary hormones, she was diagnosed with panhypopituitarism caused by metastasis of the hepatocellular carcinoma to the pituitary gland. Magnetic resonance imaging with arterial spin-labeling was effective in the differential diagnosis of the intrasellar tumor. The patient died despite hormone replacement therapy because of hypovolemic shock. Metastasis to the pituitary gland causes various non-specific symptoms, so it is difficult to diagnose. The present case emphasizes the importance of diagnostic imaging in identifying these metastases. Clinicians should consider the possibility of pituitary metastasis in patients with malignant tumors who demonstrate hypopituitarism.
- 6 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 863
Open AccessPituitary metastasis of hepatocellular carcinoma presenting with panhypopituitarism: a case report
Metastasis to the pituitary gland is extremely rare and is often detected incidentally by symptoms associated with endocrine dysfunction. Breast and lung cancer are the most common primary metastasizing to pituitary gland. Metastasis from hepatocellular carcinoma to the pituitary gland is extremely rare, with only 10 cases having been previously reported. We present here the first case of pituitary metastasis of hepatocellular carcinoma presenting with panhypopituitarism diagnosed by magnetic resonance imaging. We report the case of an 80-year-old Japanese woman who presented with the sudden onset of hypotension and bradycardia after having previously been diagnosed with hepatocellular carcinoma. Based on low levels of pituitary hormones, she was diagnosed with panhypopituitarism caused by metastasis of the hepatocellular carcinoma to the pituitary gland. Magnetic resonance imaging with arterial spin-labeling was effective in the differential diagnosis of the intrasellar tumor. The patient died despite hormone replacement therapy because of hypovolemic shock. Metastasis to the pituitary gland causes various non-specific symptoms, so it is difficult to diagnose. The present case emphasizes the importance of diagnostic imaging in identifying these metastases. Clinicians should consider the possibility of pituitary metastasis in patients with malignant tumors who demonstrate hypopituitarism.
- Open Access
- 3 September 2015
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 15 (1) , 15
Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report
The spontaneous rupture of hepatic metastases is rare compared to that of primary hepatic tumors. In addition, vemurafenib, a selective inhibitor of the mutant BRAF protein or gene product, has been reported to be extremely effective in patients with metastatic melanoma who harbor a BRAF V600E mutation. A 44-year-old female had previously undergone surgery for resection of a malignant melanoma in the lower right leg. Four years later, hepatic metastases became apparent, and transcatheter arterial embolization (TAE) was performed. Then she underwent treatment with vemurafenib. The size of the hepatic metastases markedly decreased. Two months later, they enlarged rapidly and ruptured, requiring emergency TAE. However, the patient developed hemorrhagic shock and died of renewed intra-abdominal bleeding on the 26th postoperative day. This is a rare case of ruptured hepatic metastases of malignant melanoma during treatment with vemurafenib. Postmortem examination and immunohistochemical analysis indicated reactivation of the mitogen-activated protein kinase pathway in the metastatic tumor, suggesting secondary resistance to vemurafenib as the possible underlying mechanism.
- 3 September 2015
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 15 (1) , 15
Open AccessRuptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report
The spontaneous rupture of hepatic metastases is rare compared to that of primary hepatic tumors. In addition, vemurafenib, a selective inhibitor of the mutant BRAF protein or gene product, has been reported to be extremely effective in patients with metastatic melanoma who harbor a BRAF V600E mutation. A 44-year-old female had previously undergone surgery for resection of a malignant melanoma in the lower right leg. Four years later, hepatic metastases became apparent, and transcatheter arterial embolization (TAE) was performed. Then she underwent treatment with vemurafenib. The size of the hepatic metastases markedly decreased. Two months later, they enlarged rapidly and ruptured, requiring emergency TAE. However, the patient developed hemorrhagic shock and died of renewed intra-abdominal bleeding on the 26th postoperative day. This is a rare case of ruptured hepatic metastases of malignant melanoma during treatment with vemurafenib. Postmortem examination and immunohistochemical analysis indicated reactivation of the mitogen-activated protein kinase pathway in the metastatic tumor, suggesting secondary resistance to vemurafenib as the possible underlying mechanism.
- 28 April 2009
- Published by S. Karger AG in Digestion
- Vol. 79 (4) , 235-242
The Effects of Helicobacter pylori Eradication on Body Mass Index and Dyspeptic Symptoms
Background and Aim: The relationship between Helicobacter pylori infection and body mass index (BMI) and dyspeptic symptoms is controversial. We investigated the changes in BMI and dyspeptic symptoms after H. pylori eradication among stages of atrophic gastritis classified according to the serum pepsinogen (PG) I/II ratio. Methods: One hundred and sixty-three H. pylori-positive patients underwent eradication therapy for H. pylori. Serum PG I and II concentrations were measured before treatment, and the PG I/II ratio was classified into three groups: PG I/II ratio <2.0, PG I/II ratio ≥2.0 and <4.0, and PG I/II ratio ≥4.0 were considered to be low, middle, and high, respectively. Their BMI and abdominal symptoms were checked before, 1 and 5 years after treatment, and these changes were investigated among the three groups. Results: The mean BMI changes 1 year after treatment in the low PG I/II ratio group were significantly higher than those in other groups. Most abdominal symptoms in the high PG I/II ratio group were most severe before eradication but improved significantly after eradication. Conclusions: The effects of H. pylori eradication on BMI and dyspeptic symptoms may be different according to the serum PG I/II ratio before eradication.
- 28 April 2009
- Published by S. Karger AG in Digestion
- Vol. 79 (4) , 235-242
The Effects of Helicobacter pylori Eradication on Body Mass Index and Dyspeptic Symptoms
Background and Aim: The relationship between Helicobacter pylori infection and body mass index (BMI) and dyspeptic symptoms is controversial. We investigated the changes in BMI and dyspeptic symptoms after H. pylori eradication among stages of atrophic gastritis classified according to the serum pepsinogen (PG) I/II ratio. Methods: One hundred and sixty-three H. pylori-positive patients underwent eradication therapy for H. pylori. Serum PG I and II concentrations were measured before treatment, and the PG I/II ratio was classified into three groups: PG I/II ratio <2.0, PG I/II ratio ≥2.0 and <4.0, and PG I/II ratio ≥4.0 were considered to be low, middle, and high, respectively. Their BMI and abdominal symptoms were checked before, 1 and 5 years after treatment, and these changes were investigated among the three groups. Results: The mean BMI changes 1 year after treatment in the low PG I/II ratio group were significantly higher than those in other groups. Most abdominal symptoms in the high PG I/II ratio group were most severe before eradication but improved significantly after eradication. Conclusions: The effects of H. pylori eradication on BMI and dyspeptic symptoms may be different according to the serum PG I/II ratio before eradication.